Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …

Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral …

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Introduction: The impact of vaccination and casirivimab-imdevimab monoclonal antibody
treatment on the clinical outcome of COVID-19 during a period of SARS-CoV-2 Delta surge …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS+ IMD) …

Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …